vs
Side-by-side financial comparison of JBS N.V. (JBS) and Pfizer (PFE). Click either name above to swap in a different company.
JBS N.V. is the larger business by last-quarter revenue ($22.6B vs $17.6B, roughly 1.3× Pfizer). JBS N.V. runs the higher net margin — 2.9% vs -9.4%, a 12.2% gap on every dollar of revenue. On growth, JBS N.V. posted the faster year-over-year revenue change (13.4% vs -1.2%). Pfizer produced more free cash flow last quarter ($4.5B vs $-264.6M).
JBS N.V. is a Brazilian multinational company that is the largest meat processing enterprise in the world, producing factory processed beef, chicken, salmon, sheep, pork, and also selling by-products from the processing of these meats. It is headquartered in São Paulo. It was founded in 1953 in Anápolis, Goiás.
Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City. Founded in 1849 in New York by German entrepreneurs Charles Pfizer (1824–1906) and Charles F. Erhart (1821–1891), Pfizer is one of the oldest pharmaceutical companies in North America.
JBS vs PFE — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $22.6B | $17.6B |
| Net Profit | $644.1M | $-1.6B |
| Gross Margin | 13.2% | 70.0% |
| Operating Margin | 5.4% | -9.4% |
| Net Margin | 2.9% | -9.4% |
| Revenue YoY | 13.4% | -1.2% |
| Net Profit YoY | -14.9% | -501.7% |
| EPS (diluted) | $0.52 | $-0.29 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $17.6B | ||
| Q3 25 | $22.6B | $16.7B | ||
| Q2 25 | — | $14.7B | ||
| Q1 25 | — | $13.7B | ||
| Q4 24 | — | $17.8B | ||
| Q3 24 | $19.9B | $17.7B | ||
| Q2 24 | — | $13.3B | ||
| Q1 24 | — | $14.9B |
| Q4 25 | — | $-1.6B | ||
| Q3 25 | $644.1M | $3.5B | ||
| Q2 25 | — | $2.9B | ||
| Q1 25 | — | $3.0B | ||
| Q4 24 | — | $410.0M | ||
| Q3 24 | $756.6M | $4.5B | ||
| Q2 24 | — | $41.0M | ||
| Q1 24 | — | $3.1B |
| Q4 25 | — | 70.0% | ||
| Q3 25 | 13.2% | 74.9% | ||
| Q2 25 | — | 74.2% | ||
| Q1 25 | — | 79.3% | ||
| Q4 24 | — | 66.7% | ||
| Q3 24 | 16.5% | 70.3% | ||
| Q2 24 | — | 75.2% | ||
| Q1 24 | — | 77.3% |
| Q4 25 | — | -9.4% | ||
| Q3 25 | 5.4% | 20.0% | ||
| Q2 25 | — | 20.8% | ||
| Q1 25 | — | 20.3% | ||
| Q4 24 | — | -0.1% | ||
| Q3 24 | 7.8% | 26.6% | ||
| Q2 24 | — | -0.8% | ||
| Q1 24 | — | 23.0% |
| Q4 25 | — | -9.4% | ||
| Q3 25 | 2.9% | 21.3% | ||
| Q2 25 | — | 19.9% | ||
| Q1 25 | — | 21.6% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | 3.8% | 25.2% | ||
| Q2 24 | — | 0.3% | ||
| Q1 24 | — | 20.9% |
| Q4 25 | — | $-0.29 | ||
| Q3 25 | $0.52 | $0.62 | ||
| Q2 25 | — | $0.51 | ||
| Q1 25 | — | $0.52 | ||
| Q4 24 | — | $0.07 | ||
| Q3 24 | $0.62 | $0.78 | ||
| Q2 24 | — | $0.01 | ||
| Q1 24 | — | $0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $485.5B | $1.1B |
| Total DebtLower is stronger | $213.0M | — |
| Stockholders' EquityBook value | $9.5B | $86.5B |
| Total Assets | $44.2B | $208.2B |
| Debt / EquityLower = less leverage | 0.02× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.1B | ||
| Q3 25 | $485.5B | $1.3B | ||
| Q2 25 | — | $1.6B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.0B | ||
| Q3 24 | $5.1B | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $719.0M |
| Q4 25 | — | — | ||
| Q3 25 | $213.0M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $86.5B | ||
| Q3 25 | $9.5B | $92.8B | ||
| Q2 25 | — | $88.7B | ||
| Q1 25 | — | $90.3B | ||
| Q4 24 | — | $88.2B | ||
| Q3 24 | $9.5B | $92.3B | ||
| Q2 24 | — | $87.7B | ||
| Q1 24 | — | $92.3B |
| Q4 25 | — | $208.2B | ||
| Q3 25 | $44.2B | $208.7B | ||
| Q2 25 | — | $206.1B | ||
| Q1 25 | — | $208.0B | ||
| Q4 24 | — | $213.4B | ||
| Q3 24 | — | $219.5B | ||
| Q2 24 | — | $216.2B | ||
| Q1 24 | — | $221.1B |
| Q4 25 | — | — | ||
| Q3 25 | 0.02× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $996.4M | $5.3B |
| Free Cash FlowOCF − Capex | $-264.6M | $4.5B |
| FCF MarginFCF / Revenue | -1.2% | 25.6% |
| Capex IntensityCapex / Revenue | 5.6% | 4.8% |
| Cash ConversionOCF / Net Profit | 1.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $9.1B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $5.3B | ||
| Q3 25 | $996.4M | $4.6B | ||
| Q2 25 | — | $-582.0M | ||
| Q1 25 | — | $2.3B | ||
| Q4 24 | — | $6.7B | ||
| Q3 24 | — | $6.7B | ||
| Q2 24 | — | $-1.8B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | — | $4.5B | ||
| Q3 25 | $-264.6M | $4.0B | ||
| Q2 25 | — | $-1.2B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | — | $5.8B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $-2.4B | ||
| Q1 24 | — | $386.0M |
| Q4 25 | — | 25.6% | ||
| Q3 25 | -1.2% | 24.0% | ||
| Q2 25 | — | -8.2% | ||
| Q1 25 | — | 12.9% | ||
| Q4 24 | — | 32.7% | ||
| Q3 24 | — | 34.3% | ||
| Q2 24 | — | -18.2% | ||
| Q1 24 | — | 2.6% |
| Q4 25 | — | 4.8% | ||
| Q3 25 | 5.6% | 3.6% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 4.1% | ||
| Q4 24 | — | 5.2% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 4.8% | ||
| Q1 24 | — | 4.7% |
| Q4 25 | — | — | ||
| Q3 25 | 1.55× | 1.30× | ||
| Q2 25 | — | -0.20× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | — | 16.39× | ||
| Q3 24 | — | 1.50× | ||
| Q2 24 | — | -43.44× | ||
| Q1 24 | — | 0.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JBS
Segment breakdown not available.
PFE
| U.S.Commercial Division | $9.0B | 51% |
| Specialty Care | $4.8B | 27% |
| Total Alliance Biopharmaceuticals | $2.6B | 15% |
| Royalty | $480.0M | 3% |
| Pfizer Centre One | $409.0M | 2% |
